England offers free meningococcal B vaccine to eligible university students in catch-up programme

BBC reports that thousands of students heading to university in autumn 2026 will be eligible for a free meningococcal group B vaccine following a Kent outbreak linked to two deaths. From July 20, participating pharmacies across England will offer MenB vaccinations to eligible students, with guidance on who is eligible, how the vaccine works, and how to book.

• Eligibility includes students starting university in autumn 2026 born on or after 21 July 2001, including those not yet 18.
• Two doses are recommended, spaced at least 28 days apart; the first dose provides partial protection if the second is missed.
• Check your vaccination history; some people who had MenB as babies may already be protected and may not be the main target of this catch-up.
• MenB protects only MenB; MenACWY covers other meningitis strains; together they provide broad protection.
• Booking is preferred but walk-in options may be available; bring evidence of eligibility such as a UCAS offer letter or university email to the vaccination centre.

Overview

In response to a meningitis B outbreak in Kent linked to two deaths, England is launching a catch-up programme to vaccinate eligible university students with the meningococcal group B (MenB) vaccine. Beginning July 20, participating pharmacies across England will offer MenB vaccinations to students who are starting university in autumn 2026. Eligibility covers students born on or after July 21 2001, including those who have not yet turned 18. NHS guidance and local pharmacies, GPs or university student services can confirm individual eligibility.

What the vaccine does

The MenB vaccine protects against meningococcal group B bacteria, a leading cause of meningitis and septicaemia in young people. It does not protect against all meningitis-causing pathogens. Other strains such as A, C, W and Y are covered by MenACWY vaccines, which are routinely offered to teenagers and university entrants. Taken together, MenB and MenACWY vaccines provide protection against the major meningococcal strains in the UK.

Eligibility and vaccination history

If you were vaccinated with the MenB vaccine as part of the routine infant programme introduced in 2015, you should already have protection and are not the main target of this catch-up. Those who did not receive MenB as infants but are entering university for the first time in autumn 2026 should check their vaccination history and NHS guidance. If unsure, talk to a participating pharmacy, GP, or your university’s student advice service.

Booking, access and evidence

Vaccinations are preferably booked in advance, though some pharmacies may offer walk-in appointments. It is advisable to check availability with the pharmacy beforehand. When attending for the first time, bring evidence such as a UCAS offer, offer letter, or an email from the university to confirm eligibility.

Dosing schedule and what happens if you miss a dose

The NHS programme recommends two doses given at least 28 days apart. If you miss the second dose, arrange to complete the course as soon as possible. You generally do not need to retake the first dose, but you should complete the second dose to gain full protection.

Symptoms awareness and personal protection

Even with MenB vaccination, no vaccine is 100% effective and meningitis can be caused by other bacteria and viruses. Be alert to meningitis symptoms such as fever, severe headache, vomiting, stiff neck, sensitivity to light, rash, confusion, and dizziness. Septicaemia signs include fever with shivering, cold hands and feet, rapid breathing, a red or purple non-fading rash, and deterioration in consciousness. Early diagnosis and treatment are essential.

Additional context

While MenB targets group B meningococcal disease, the broader strategy relies on combining MenB with MenACWY vaccines to cover the most important meningococcal strains in the UK. University students are prioritized due to high close-contact living arrangements, which can increase the spread risk in the first year. Vaccination remains a key preventive measure, but continued vigilance for symptoms is important even after vaccination.